Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Fadi EL KARAK"'
Autor:
Aline Hajj, Rita Khoury, Roula Hachem, Aya Awad, Souheil Hallit, Hala Sacre, Fady Nasr, Fadi El Karak, Georges Chahine, Joseph Kattan, Lydia Rabbaa Khabbaz
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Breast cancer patients undergoing chemotherapy treatment are at particular risk of experiencing acute cognitive impairment leading to daily challenges in decision-making and reduced quality of life and functional autonomy. The aim
Externí odkaz:
https://doaj.org/article/cb9ed34ce9554b0da298f8e0d527ca8a
Autor:
Aline HAJJ, Roula HACHEM, Rita KHOURY, Souheil HALLIT, Bashar ElJEBBAWI, Fady NASR, Fadi EL KARAK, Georges CHAHINE, Joseph KATTAN, Lydia RABBAA KHABBAZ
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Despite the progress in assessment and treatment of breast cancer, being diagnosed with it or receiving chemotherapy treatment is still conceived as a traumatic experience. Women develop negative thoughts about life and death with
Externí odkaz:
https://doaj.org/article/65fbb06acf0c4b41b9f6ccf0a507b95c
Autor:
Arafat Tfayli, Majd Al Assaad, Ghina Fakhri, Reem Akel, Hanine Atwi, Hady Ghanem, Fadi El Karak, Fadi Farhat, Kamal Al Rabi, Pierre Sfeir, Pierre Youssef, Ziad Mansour, Hazem Assi, Mohamad Haidar, Alain Abi Ghanem, Ibrahim Khalifeh, Fouad Boulos, Ramy Mahfouz, Bassem Youssef, Youssef Zeidan, Rachelle Bejjany, Fadlo Khuri
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8406-8411 (2020)
Abstract Multiple randomized studies have shown that combination of chemotherapy and immune checkpoint inhibitors (ICIs) leads to better response rates and survival as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting a b
Externí odkaz:
https://doaj.org/article/d6eb58e736a745a1befdf7c504496b67
Autor:
Marwan Ghosn, Roland Eid, Emad Hamada, Hamdy Abdel Azim, Jamal Zekri, Mubarak Al-Mansour, Mohammed Jaloudi, Fadi Nasr, Hassan Errihani, Adda Bounedjar, Amel Mezlini, Hamouda Boussen, Joseph Kattan, Fadi El Karak, Fadi Farhat, on behalf of the Africa Middle East Cancer Intergroup
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-10 (2019)
PURPOSE: Sunitinib offers improved efficacy for patients with metastatic renal cell carcinoma (mRCC). To provide better disease management in the Middle East, we studied its use in mRCC in real-life practice in this region. MATERIAL AND METHODS: Pati
Externí odkaz:
https://doaj.org/article/72f22944eb3a4a5ab951dcde96a8f7f9
Autor:
Nour Abdul Halim, Rola El Sayed, Ibrahim A. Alameh, Jessica Khoury, Clara El Nakib, Maroun Bou Zerdan, Maya Charafeddine, Fadi Farhat, Fadi El Karak, Hazem I. Assi
Publikováno v:
Cancer Treatment and Research Communications, Vol 26, Iss , Pp 100275- (2021)
Introduction: Sarcomas are uncommon malignancies. No advances have been recently achieved despite multiple efforts. Pazopanib is a safe and effective tyrosine kinase inhibitor used in managing soft tissue sarcomas (STS) after chemotherapy failure. Ho
Externí odkaz:
https://doaj.org/article/dc0f132f975147388599a31f494987f0
Autor:
Fadi El Karak, Ibrahim R Bou-Orm, Marwan Ghosn, Joseph Kattan, Fadi Farhat, Toni Ibrahim, Mario Jreige, Jean El Cheikh, Mohamad Haidar
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170299 (2017)
Evaluation of bone marrow involvement (BMI) is paramount in diffuse large B-cell lymphoma (DLBCL) for prognostic and therapeutic reasons. PET/CT scanner (PET) is now a routine examination for the staging of DLBCL with prognostic and therapeutic impli
Externí odkaz:
https://doaj.org/article/dfb31a92e4064ac38fa402f9b9c3264d
Publikováno v:
Leukemia Research Reports, Vol 4, Iss 2, Pp 42-44 (2015)
Central nervous system (CNS) relapse is not a rare presentation in acute myeloid leukemia (AML) as its incidence ranges between 2% and 9%. It manifests with meningeal leukemia, cranial nerve palsies or cerebral mesenchymal myeloid sarcoma. We herein
Externí odkaz:
https://doaj.org/article/cff247923093499eb5638bd3ec5de8b0
Autor:
Hazem I. Assi, Maroun Bou Zerdan, Mohammad Hodroj, Makram Khoury, Nour Sabiha Naji, Ghid Amhaz, Reine Abou Zeidane, Fadi El Karak
Publikováno v:
Oncotarget. 14:517-525
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54097587a0a47ebf021bcad70c298d2b
https://doi.org/10.18632/oncotarget.28444
https://doi.org/10.18632/oncotarget.28444
Autor:
Marwan Ghosn, Joseph Kattan, Fadi El Karak, Hady Ghanem, Jamil Debs, Khaled Ibrahim, Ali Shamseddine
Publikováno v:
Future Oncology.
Renal cell carcinoma (RCC) management has seen a revolution over the last decades. Six Lebanese oncologists discussed recent updates in RCC management and outlined the challenges and future directions in Lebanon. Sunitinib continues to be a first-lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64b796e91de9331d247cd5b9b95e2bc8
https://doi.org/10.2217/fon-2021-1189
https://doi.org/10.2217/fon-2021-1189
Autor:
Pathmanathan Rajadurai, Tatiana Semiglazova, Alinta Hegmane, Fadi El Karak, Joanne W Chiu, Sudeep Gupta, Hamdy A Azim, Josef JEM Kitzen, Antoine Arnaud, Sina Haftchenary, Jiwen Wu, Lakshmi Menon-Singh, LaTonya Smith, Lyudmila Zhukova
Publikováno v:
Cancer Research. 82:P5-13
Introduction: PIK3CA mutations (mut) occur in ~40% of patients (pts) with HR+, HER2- ABC, and lead to phosphatidylinositol 3-kinase (PI3K) pathway hyperactivation, endocrine resistance, and poor survival in advanced disease. Alpelisib, an α-selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fe5d52c174dbca4c02d40794c7cbea9
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-25
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-25